Thomas Schinecker, Roche CEO
October 22, 2026 06:21 AM EDT
Roche talks up Phase 3 success rate as it unveils pipeline cuts
Where other European pharmas — notably Novartis, Novo and AstraZeneca — have suffered huge late-stage clinical failures this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
ENDPOINTS CAREERS